Brief Summary
This is an open-label, multicenter, and nonrandomized dosethe amount of medication taken escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advancedat a late stage, far along solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Intervention / Treatment
- Drug: BGB-26808
- Drug: Tislelizumab
Inclusion Criteria
- Able to provide a signed and dated written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. prior to any study-specific procedures, sampling, or data collection.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status ≤ 1.
- Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors that are immune-sensitive who have been previously treated.
- ≥ 1 measurable lesion per RECIST v1.1.
- Able to provide an archived tumor tissuea group of cells that work together to perform a function sample.
- Adequate organ function.
- Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 90 days after the last dose of BGB-26808 or for ≥ 120 days after the last dose of tislelizumab.
- Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 90 days after the last dose of BGB-26808 or for ≥ 120 days after the last dose of tislelizumab.